SGLT2 inhibitors are a new class of oral hypoglycemic drugs that reduce glucosereabsorption and lower blood glucose levels by inhibiting SGLT2 in renal tubules.Although SGLT2 is not expressed in the heart, the cardiac off-target effect ofSGLT2 inhibitors offers potential for treating HF through a mechanism that mayinvolve the activation of AMPK, which regulates energy metabolism, inflammatoryresponses, oxidative stress, and autophagy. The gene discussed is SLC5A2; the disease is hydrops fetalis.